Chin, Keisho
Yamamoto, Shun
Takahashi, Masanobu
Kadowaki, Shigenori
Kubota, Yutaro
Amanuma, Yusuke
Okada, Morihito
Kanda, Mitsuro
Kimura, Yasue
Nogi, Yuhiko
Arimitsu, Yuko
Kitagawa, Yuko
Funding for this research was provided by:
Ono Pharmaceuticals, Co., Ltd.
Bristol Myers Squibb
Article History
Received: 29 March 2022
Accepted: 28 November 2022
First Online: 23 December 2022
Declarations
:
: The present study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical Research Involving Human Subjects. The study protocol was approved by the ethical review board of each institute. All patients or their legal representatives provided written informed consent and were given the opportunity to opt out.
: Keisho Chin received grants from Bristol Myers Squibb and Ono for this study; and honoraria from Bristol Myers Squibb, Chugai, Ono, and Taiho, outside of the submitted work. Shun Yamamoto received grants from Bristol Myers Squibb and Ono for this study; and honoraria from Ono, outside the submitted work. Masanobu Takahashi received grants from Bristol Myers Squibb and Ono for this study; and grants from Chugai and Ono; and honoraria from Bristol Myers Squibb, Daiichi Sankyo, and Ono, outside the submitted work. Shigenori Kadowaki received grants from Bristol Myers Squibb and Ono for this study; grants from Chugai, Daiichi Sankyo, Eli Lilly, MSD, Nobelpharma, Ono, Taiho, and Janssen; and honoraria from Bayer, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Merck Serono, Ono, and Taiho, outside of the submitted work. Yutaro Kubota, Yusuke Amanuma, Mitsuro Kanda, and Yasue Kimura received grants from Bristol Myers Squibb and Ono for this study. Morihito Okada received grants from Bristol Myers Squibb and Ono for this study; and grants from AstraZeneca, Bristol Myers Squibb, Chugai, Clinipace, Covidien, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Kissei, Kyorin, Kyowa Kirin, Mitsubishi Tanabe, MSD, Nihon Medi-Physics, Ono, Parexel, and Taiho; and honoraria from AstraZeneca, Bristol Myers Squibb, Chugai, Covidien, Daiichi Sankyo, Johnson & Johnson, Kyorin, MSD, and Pfizer, outside of the submitted work. Yuhiko Nogi is an employee of Bristol Myers Squibb. Yuko Arimitsu is an employee and a stock holder of Ono. Yuko Kitagawa received grants from Bristol Myers Squibb and Ono for this study; and grants from Asahi Kasei, Astellas, Chugai, Dainippon Sumitomo, EA Pharma, Eisai, Kaken, Kyowa Hakko Kirin, Medicon, Nihon, Nippon Covidien, Ono, Otsuka, Otsuka Pharmaceutical Factory, Taiho, Takeda, Teijin, Toyama Chemical, Tsumura, and Yakult Honsha; honoraria from Asahi Kasei, AstraZeneca, Bristol Myers Squibb, Chugai, Ethicon, Kaken, MSD, Nippon Covidien, Olympus, Ono, Otsuka, Shionogi, Smith & Nephew, and Taiho; and personal fees from Bristol Myers Squibb and Ono, outside of the submitted work.